The Second Clinical Medical College, 70571Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (lung and esophagus), Cancer Hospital of the University of Chinese Academy of Sciences (89680Zhejiang Cancer Hospital), People's Republic of China.
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211036526. doi: 10.1177/15330338211036526.
Cancer is the second leading cause of death in the worldwide. With the growing burden of cancer, the studies on early diagnosis, treatment and prevention of cancer are rapidly increasing. Recently, many new therapeutic strategies have been discovered, among which immunotherapy has dramatically changed the outlook for cancer treatment. Several clinical trials are underway around the world to produce potential treatments. However, these trials set certain strict joining conditions, so that the clinical data cannot be fully applied in the real world. To help clinical oncologists with treatment decision-making, this review collected recent studies on special populations receiving immunotherapy, including organ transplant patients, pregnant women, pediatric patients, patients with pulmonary tuberculosis, patients with human immunodeficiency virus, and patients with autoimmune diseases and mental illness.
癌症是全球范围内的第二大死亡原因。随着癌症负担的不断增加，癌症的早期诊断、治疗和预防研究迅速增加。最近，已经发现了许多新的治疗策略，其中免疫疗法极大地改变了癌症治疗的前景。世界各地正在进行多项临床试验以产生潜在的治疗方法。然而，这些试验设定了某些严格的加入条件，使得临床数据无法在现实世界中充分应用。为了帮助临床肿瘤学家做出治疗决策，本综述收集了最近关于接受免疫治疗的特殊人群的研究，包括器官移植患者、孕妇、儿科患者、肺结核患者、人类免疫缺陷病毒患者以及自身免疫性疾病和精神疾病患者。
